BioAtla (BCAB) to Release Quarterly Earnings on Thursday

BioAtla (NASDAQ:BCAB) is set to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.

BioAtla (NASDAQ:BCAB) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01. During the same period in the previous year, the company earned ($0.75) earnings per share. On average, analysts expect BioAtla to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BioAtla Trading Up 1.6 %

NASDAQ BCAB traded up $0.03 during trading hours on Friday, hitting $1.95. 33,660 shares of the company’s stock traded hands, compared to its average volume of 824,646. The firm has a market capitalization of $94.26 million, a P/E ratio of -0.88 and a beta of 1.06. BioAtla has a 52 week low of $1.14 and a 52 week high of $4.02. The business’s fifty day moving average price is $1.87 and its two-hundred day moving average price is $1.90.

Wall Street Analyst Weigh In

Separately, JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of BioAtla in a research note on Monday, September 16th.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.